Literature DB >> 1370874

Dominant negative and loss of function mutations of the c-kit (mast/stem cell growth factor receptor) proto-oncogene in human piebaldism.

R A Spritz1, L B Giebel, S A Holmes.   

Abstract

Piebaldism is an autosomal dominant disorder of melanocyte development and is characterized by congenital white patches of skin and hair from which melanocytes are completely absent. A similar disorder of the mouse, "dominant white spotting" (W), results from mutations of the c-kit proto-oncogene, which encodes the cellular tyrosine kinase receptor for the mast/stem cell growth factor. We have identified c-kit gene mutations in three patients with piebaldism. A missense substitution (Phe----Leu) at codon 584, within the tyrosine kinase domain, is associated with a severe piebald phenotype, whereas two different frameshifts, within codons 561 and 642, are both associated with a variable and relatively mild piebald phenotype. This is consistent with a possible "dominant negative" effect of missense c-kit polypeptides on the function of the dimeric receptor.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1370874      PMCID: PMC1682440     

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  26 in total

1.  Familial white skin spotting (piebaldness) ("partial albinism") with white forelock.

Authors:  J V COOKE
Journal:  J Pediatr       Date:  1952-07       Impact factor: 4.406

Review 2.  Receptor tyrosine kinases: genetic evidence for their role in Drosophila and mouse development.

Authors:  T Pawson; A Bernstein
Journal:  Trends Genet       Date:  1990-11       Impact factor: 11.639

Review 3.  Functional inactivation of genes by dominant negative mutations.

Authors:  I Herskowitz
Journal:  Nature       Date:  1987 Sep 17-23       Impact factor: 49.962

4.  Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase.

Authors:  R K Saiki; D H Gelfand; S Stoffel; S J Scharf; R Higuchi; G T Horn; K B Mullis; H A Erlich
Journal:  Science       Date:  1988-01-29       Impact factor: 47.728

5.  Tentative assignment of piebald trait gene to chromosome band 4q12.

Authors:  J J Hoo; R H Haslam; C van Orman
Journal:  Hum Genet       Date:  1986-07       Impact factor: 4.132

6.  Dominant piebald trait in a retarded child with a reciprocal translocation and small intercalary deletion.

Authors:  S J Funderburk; B F Crandall
Journal:  Am J Hum Genet       Date:  1974-11       Impact factor: 11.025

7.  Piebaldness with Hirschsprung's disease.

Authors:  A Mahakrishnan; M S Srinivasan
Journal:  Arch Dermatol       Date:  1980-10

8.  Stem cell factor is encoded at the Sl locus of the mouse and is the ligand for the c-kit tyrosine kinase receptor.

Authors:  K M Zsebo; D A Williams; E N Geissler; V C Broudy; F H Martin; H L Atkins; R Y Hsu; N C Birkett; K H Okino; D C Murdock
Journal:  Cell       Date:  1990-10-05       Impact factor: 41.582

9.  Exon skipping by mutation of an authentic splice site of c-kit gene in W/W mouse.

Authors:  S Hayashi; T Kunisada; M Ogawa; K Yamaguchi; S Nishikawa
Journal:  Nucleic Acids Res       Date:  1991-03-25       Impact factor: 16.971

10.  Interstitial deletion of the proximal long arm of chromosome 4 associated with father-child incompatibility within the Gc-system: probable reduced gene dosage effect and partial piebald trait.

Authors:  Y Yamamoto; H Nishimoto; S Ikemoto
Journal:  Am J Med Genet       Date:  1989-04
View more
  19 in total

Review 1.  Targeting KIT in melanoma: a paradigm of molecular medicine and targeted therapeutics.

Authors:  Scott E Woodman; Michael A Davies
Journal:  Biochem Pharmacol       Date:  2010-05-08       Impact factor: 5.858

2.  KIT with D816 mutations cooperates with CBFB-MYH11 for leukemogenesis in mice.

Authors:  Ling Zhao; Jan J Melenhorst; Lemlem Alemu; Martha Kirby; Stacie Anderson; Maggie Kench; Shelley Hoogstraten-Miller; Lauren Brinster; Yasuhiko Kamikubo; D Gary Gilliland; P Paul Liu
Journal:  Blood       Date:  2011-12-07       Impact factor: 22.113

3.  Effect of the c-kit codon 584 Phe----Leu substitution demonstrated in human piebaldism.

Authors:  R A Fleischman
Journal:  Am J Hum Genet       Date:  1992-09       Impact factor: 11.025

Review 4.  Interstitial deletion of bands 4q12-->q13.1: case report and review of proximal 4q deletions.

Authors:  A Slavotinek; H Kingston
Journal:  J Med Genet       Date:  1997-10       Impact factor: 6.318

5.  Biphasic expression of two paracrine melanogenic cytokines, stem cell factor and endothelin-1, in ultraviolet B-induced human melanogenesis.

Authors:  Akira Hachiya; Akemi Kobayashi; Yasuko Yoshida; Takashi Kitahara; Yoshinori Takema; Genji Imokawa
Journal:  Am J Pathol       Date:  2004-12       Impact factor: 4.307

6.  Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis.

Authors:  B J Longley; D D Metcalfe; M Tharp; X Wang; L Tyrrell; S Z Lu; D Heitjan; Y Ma
Journal:  Proc Natl Acad Sci U S A       Date:  1999-02-16       Impact factor: 11.205

7.  Subregional mapping of the human gonadotropin-releasing hormone receptor (GnRH-R) gene to 4q between the markers D4S392 and D4S409.

Authors:  M L Kottler; F Lorenzo; F Bergametti; P Commerçon; C Souchier; R Counis
Journal:  Hum Genet       Date:  1995-10       Impact factor: 4.132

8.  Mutations of the KIT (mast/stem cell growth factor receptor) proto-oncogene account for a continuous range of phenotypes in human piebaldism.

Authors:  R A Spritz; S A Holmes; R Ramesar; J Greenberg; D Curtis; P Beighton
Journal:  Am J Hum Genet       Date:  1992-11       Impact factor: 11.025

Review 9.  Mouse homologues of human hereditary disease.

Authors:  A G Searle; J H Edwards; J G Hall
Journal:  J Med Genet       Date:  1994-01       Impact factor: 6.318

10.  Human piebald trait resulting from a dominant negative mutant allele of the c-kit membrane receptor gene.

Authors:  R A Fleischman
Journal:  J Clin Invest       Date:  1992-06       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.